Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06499870
Title Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Acronym OPTIMAL
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.